OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The su ...

CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, f ...

采用云原生 Mavenir BSS 和核心网，与 TextNow 聚焦长期创新的战略相契合旧金山和德克萨斯州理查森市, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 美国领先的广告支持型免费无线服务提供商 TextNow 与颠覆性云原生电信技术提供商 Mavenir 今日宣布，将 Mavenir 的云原生 BSS 和核心网 (Core) 集成到 TextNow 的移动虚拟网络运营商 (MVNO) 基础设施中。 Mavenir 的云原生 BSS 和核心网平台解决方案旨在帮助 TextNow 更快地接纳新用户、推出差异化的服务层级，并扩展其免费无线模式，以覆盖更多正在寻求优质无线服务而又不愿支付过高费用的数百万美国民众。 此次与 Mavenir 的集成突显了 TextNow 对创新的关注，它提供了一系列功能来更好地支持 TextNow 超过 800 万的活跃用户，包括管理赞助合作伙伴、发展漫游合作关系以及为用户配置独立 SIM 卡档案的能力。 TextNow 合作与创新高级副总裁 Tristan Huntington 表示：“TextNow 花了 17 年时间证明，无线服务可以是免费的，可以 ...

Core Viewpoint - Euroseas Ltd. reported strong financial results for the fourth quarter and full year of 2025, highlighting high profitability and robust charter rates, while also addressing challenges in the containership market [4][5][6]. Fourth Quarter 2025 Financial Highlights - Total net revenues reached $57.4 million, a 7.7% increase from $53.3 million in Q4 2024, driven by higher average time charter rates despite a decrease in the average number of vessels operated [9][12]. - Net income for the quarter was $40.5 million, compared to $24.4 million in Q4 2024, with earnings per share of $5.82 (basic) and $5.79 (diluted) [7][23]. - The average time charter equivalent rate for the quarter was $30,268 per day, up from $26,479 per day in the same period last year [12][41]. - Adjusted EBITDA for Q4 2025 was $40.7 million, an increase from $32.8 million in Q4 2024 [11][22]. Full Year 2025 Highlights - Total net revenues for 2025 were $227.9 million, a 7.0% increase from $212.9 million in 2024, attributed to a higher number of vessels and increased charter rates [25]. - Net income for the year was $137.0 million, up from $112.8 million in 2024, with earnings per share of $19.73 (basic) and $19.72 (diluted) [36]. - The average time charter equivalent rate for the year was $29,107 per day, compared to $28,054 per day in 2024 [25][41]. - Adjusted EBITDA for the full year was $155.9 million, compared to $135.8 million in 2024 [35]. Fleet and Charter Coverage - The company has a charter coverage of approximately 87% for 2026 and over 71% for 2027, with contracted revenues exceeding $550 million over the next five years [5][6]. - The fleet operated an average of 22.22 vessels in 2025, compared to 21.73 vessels in 2024 [25][41]. Market Conditions and Challenges - The containership market faces challenges such as high orderbook levels in large containership segments and potential reductions in demand due to resumed traffic through the Suez Canal [6]. - Euroseas operates in the feeder and intermediate size vessel segments, which are expected to see a contraction in supply, benefiting modern vessel owners [6]. Shareholder Returns - The company declared a quarterly dividend of $0.75 per share for Q4 2025, reflecting a 7% increase and providing an annualized yield of about 5% [8]. - As of February 25, 2026, the company repurchased 480,455 shares, representing about 6.8% of outstanding shares, under a $20 million share repurchase plan [7].

Core Insights - Intelligent Bio Solutions Inc. has successfully received and deployed its first shipment of Intelligent Fingerprinting Drug Screening Readers through a partnership with Syrma Johari, marking a significant step in scaling production capacity and validating the operational and financial benefits of the collaboration [1][3] - The partnership is expected to deliver annual production cost savings of over 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin annually [1][3] - The company has doubled its in-house production capacity for lateral flow test strips, enhancing vertical integration and accelerating research and development [1][4] Production and Manufacturing - The first shipment of readers is being deployed across key customer verticals such as construction, transportation, logistics, and manufacturing in the U.K. and Europe, supporting growing commercial demand [2] - The partnership with Syrma Johari has provided access to manufacturing capacity approximately four times greater than prior capabilities, allowing for accelerated fulfillment and cost savings [3] - The company has sourced advanced manufacturing equipment that has doubled its in-house production capacity for lateral flow test strips, improving margins and reducing lead times [4] Strategic Positioning - The successful deployment of the first shipment and increased production capacity positions the company to enter the U.S. market with operational strength and the ability to grow with demand [5] - The company is building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion and accelerates innovation [5] - Additional production shipments are expected throughout 2026 as the company continues to build inventory and expand its commercial footprint [5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system is designed to screen for recent drug use in workplace settings, providing results in under ten minutes, which is valuable for employers in safety-critical industries [6] - Current customer segments outside the U.S. include construction, manufacturing, transport, logistics, mining, drug treatment organizations, and coroners [6]

Core Insights - Shanghai experienced a significant increase in cultural and tourism consumption during the Spring Festival, with over 2,570 activities launched to attract visitors [1][2][4] Visitor Statistics - The city welcomed 21.6721 million visitors, marking an 8.36% year-on-year increase [3] - Total tourism consumption reached 25.614 billion yuan, a surge of 20.90% from the previous year [3] - The average hotel occupancy rate rose to 50.60%, up 3.10 percentage points year-on-year [3] Promotional Strategies - The promotion campaign utilized the outcomes of a high-level competition to enhance Shanghai's tourism appeal, integrating cultural, tourism, commerce, sports, and exhibition resources [4] - Over 130 in-depth Spring Festival tour routes were created, which became popular on online travel agencies through live-stream sales [5] Cultural Activities - Shanghai introduced premium IPs and launched 353 themed activities on the "Hu Xiaoyou" smart travel service platform, promoting science popularization and industrial tourism [6] - Key cultural landmarks hosted Spring Festival fairs and concerts, creating new urban rituals and attracting fans nationwide [7] Festive Atmosphere - The combination of traditional Chinese New Year vibes and modern cultural elements enhanced the festive atmosphere, with city-wide lantern shows illuminating the nights [8] - Intangible cultural heritage fairs and master chefs' kitchens were established, offering visitors authentic local culinary experiences [9] Future Outlook - Shanghai aims to further integrate cultural and tourism resources, pursue continuous product innovation, and enhance the overall experience of its cultural and tourism industry [10]

Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. for allegedly misleading investors regarding its IPO documents, particularly concerning undisclosed increases in sales and marketing expenses [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired Navan shares from October 28, 2025, to February 23, 2026, including during the IPO [1][2]. - Investors have until April 24, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Impact - Navan's shares have seen a significant decline, trading as low as $9.01 per share, which represents a drop of over 60% from the IPO price of $25 per share [3]. - The decline in share price has resulted in substantial losses for investors as the true state of the company's business was revealed [3]. Group 3: Company Overview - Navan, headquartered in Palo Alto, California, specializes in booking and expense reporting software for business travelers [2].

Core Insights - Silynxcom Ltd. has received a follow-on purchase order from an Asia-Pacific special forces unit for its advanced in-ear communication systems, indicating strong demand for its products in military applications [1][2]. Group 1: Product Features and Technology - The repeat order includes products with "talk-through-the-ear" technology, which enhances situational awareness and provides superior hearing protection in high-noise environments [2]. - The systems are designed for elite operators to maintain clear communication while protecting against both impulse and continuous noise, making them suitable for special operations [2]. Group 2: Company Reputation and Market Position - The CEO of Silynxcom expressed honor at the continued confidence shown by the special forces unit, viewing repeat business as a strong endorsement of the company's combat-proven solutions [3]. - The company emphasizes the reliability and operational value of its proprietary in-ear solutions, highlighting its growing traction in demanding international markets [3]. Group 3: Company Overview - Silynxcom Ltd. develops and sells ruggedized tactical communication headset devices that are field-tested and combat-proven, used in various high-stakes environments [4]. - The company's in-ear headsets integrate with professional-grade ruggedized radios, allowing users to communicate clearly while being protected from hazardous sounds [4]. - Silynxcom collaborates closely with military and law enforcement customers to enhance product functionality based on real-world feedback [4].

Core Insights - PolyPid Ltd. is an innovative biopharmaceutical company focused on enhancing treatment effectiveness at the point of care, with a diverse pipeline addressing unmet medical needs [4] Company Participation in Conferences - PolyPid management will participate in two investor conferences in March 2026, providing opportunities for one-on-one meetings with investors [2][3] Product Development - PolyPid's lead product, D-PLEX₁₀₀, has successfully met its primary and all key secondary endpoints in the Phase 3 SHIELD II trial aimed at preventing surgical site infections [4]

VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- RZOLV Technologies Inc. (TSXV:RZL – OTCQB:RZOLF), based in Vancouver Canada, and focused on disruptive gold recovery technologies, announced today that Duane Nelson, CEO, will present live at the Clean Energy & Renewables Virtual Investor Conference hosted by VirtualInvestorConferences.com, on March 5th, 2026 DATE: March 5th TIME: 1:00 PM ET REGISTER HERE Available for 1x1 meetings: March 9th– 13th. Schedule 1x1 Meetings here. This will be a liv ...